Maia Wealth LLC Purchases Shares of 14,602 Biomea Fusion, Inc. (NASDAQ:BMEA)

Maia Wealth LLC purchased a new stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 14,602 shares of the company’s stock, valued at approximately $62,000.

Several other large investors have also added to or reduced their stakes in BMEA. FMR LLC grew its stake in Biomea Fusion by 0.7% during the 3rd quarter. FMR LLC now owns 5,431,525 shares of the company’s stock valued at $54,858,000 after purchasing an additional 39,959 shares during the last quarter. Wexford Capital LP grew its stake in Biomea Fusion by 26.9% during the 3rd quarter. Wexford Capital LP now owns 130,336 shares of the company’s stock valued at $1,316,000 after purchasing an additional 27,619 shares during the last quarter. Barclays PLC boosted its stake in shares of Biomea Fusion by 156.3% in the third quarter. Barclays PLC now owns 39,620 shares of the company’s stock worth $401,000 after buying an additional 24,162 shares during the last quarter. Quest Partners LLC boosted its stake in shares of Biomea Fusion by 528.3% in the third quarter. Quest Partners LLC now owns 19,553 shares of the company’s stock worth $197,000 after buying an additional 16,441 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Biomea Fusion in the fourth quarter worth about $58,000. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Biomea Fusion in a research note on Tuesday, January 14th. D. Boral Capital restated a “buy” rating and issued a $128.00 target price on shares of Biomea Fusion in a research note on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Biomea Fusion has a consensus rating of “Buy” and a consensus target price of $39.36.

Biomea Fusion Trading Down 8.7 %

Shares of BMEA stock opened at $2.64 on Tuesday. The company has a market capitalization of $95.67 million, a P/E ratio of -0.66 and a beta of -0.34. The business’s 50 day moving average is $3.84 and its two-hundred day moving average is $6.60. Biomea Fusion, Inc. has a 12-month low of $2.58 and a 12-month high of $18.50.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.